American Journal of Pharmacy and Health Research AJPHR 2321-3647 10.5281/zenodo.20285803 AJPHR5140002 INVESTIGATING CLINICAL OUTCOMES OF ALPHA-BLOCKER MONOTHERAPY COMPARED TO COMBINED 5-ARI PROTOCOLS IN THE CONTEXT OF BENIGN PROSTATIC HYPERPLASIA VANI G. SALEEM SK.ABDUL SARASWATHI G. JAGADAMBA LAKSHMI KUMAR K. ANAND RAJU M. DEVID KUMAR G. KIRAN BABU M. KISHORE QIS College of Pharmacy, Vengamukkapalem, Pondur Road, Ongole – 523001, Andhra Pradesh, India Professor, and HOD Department of pharmacology, QIS College of Pharmacy Scholars, Pharm D, QIS College of Pharmacy Associate Professor, M.S, M.Ch, Department of Urology, Government General Hospital Principal and Professor, QIS College of Pharmacy 05 19 2026 14 5 27 39

Benign prostatic hyperplasia (BPH) is a common condition in elderly men characterized by prostate enlargement, resulting in lower urinary tract symptoms (LUTS) that significantly impact quality of life. Pharmacological management includes alpha-blockers and 5-alpha reductase inhibitors (5-ARIs). To compare the clinical outcomes of alpha-blocker monotherapy with combination therapy in patients with BPH. A 6-month prospective comparative study was conducted in 100 patients with moderate to severe BPH. Patients were treated with either alpha-blocker monotherapy or combination therapy (alpha-blocker with 5-ARI). Clinical outcomes were evaluated using the International Prostate Symptom Score (IPSS) at baseline and after 3 months. Statistical analysis was performed with significance set at p

 Benign prostatic hyperplasia alpha-blockers 5-alpha reductase inhibitors combination therapy IPSS score prostate volume.